Thanks JTFM. That was the most thorough response to a question I have ever received on IHub. If there were even a hint that Libigel was causing a 70% reduction in breast cancer in women, wouldn’t there be an ethical responsibility to let the medical scientific world know about it, in the interest of saving lives? Also the cardiovascular (heart attack) lives that could have been potentially saved? Justice demands an answer to what happened.
As far as libido goes I think that it is widely known by behavioral neurologists to be effective treatment in women. Compounding pharmacies do a big business. Did Biosante screw up the way that they and the FDA set up the pivotal clinical trial? I remember , and this was reported on a PBS radio live announcement, that it was both effective and safe, but that the placebo group did better than the treatment group. With female psychology being such a major factor in female sex drive, perhaps you might reasonably expect to have difficulties in measuring a positive clinical effect?
I remember that the trial cost $30 million dollars, money derived from shareholders and mostly suddenly down the drain at that brief instant in time.
I bought 10X shares at that low. ANIP saved my investment with their merger and solid performance that first year. We all thought that ANIP was going to take the ball with Libigel and run with it. Instead it was an agonizing silence about Libigel.
I now have a lot of PTN (Palatin) that has a female aphrodisiac drug fully FDA approved called Vyleesi. It works for both men and women, but somehow failed so far in the market, mostly due to their partner AMAG. Women’s sex drive is a tough nut to crack it seems.
I wish Art Pryzbyl would be willing so talk about it a little bit.
